GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (BSP:A1SN34) » Definitions » EV-to-EBITDA

Ascendis Pharma AS (BSP:A1SN34) EV-to-EBITDA : -4.25 (As of Jun. 03, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Ascendis Pharma AS EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ascendis Pharma AS's enterprise value is R$6,087 Mil. Ascendis Pharma AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was R$-1,432 Mil. Therefore, Ascendis Pharma AS's EV-to-EBITDA for today is -4.25.

The historical rank and industry rank for Ascendis Pharma AS's EV-to-EBITDA or its related term are showing as below:

BSP:A1SN34' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.19   Med: -14.16   Max: -3.47
Current: -43.19

During the past 13 years, the highest EV-to-EBITDA of Ascendis Pharma AS was -3.47. The lowest was -43.19. And the median was -14.16.

BSP:A1SN34's EV-to-EBITDA is ranked worse than
100% of 493 companies
in the Biotechnology industry
Industry Median: 8.54 vs BSP:A1SN34: -43.19

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-03), Ascendis Pharma AS's stock price is R$66.90. Ascendis Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was R$-35.570. Therefore, Ascendis Pharma AS's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Ascendis Pharma AS EV-to-EBITDA Historical Data

The historical data trend for Ascendis Pharma AS's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS EV-to-EBITDA Chart

Ascendis Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.53 -17.01 -12.02 -16.50 -28.15

Ascendis Pharma AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.55 -23.12 -31.13 -28.15 -38.28

Competitive Comparison of Ascendis Pharma AS's EV-to-EBITDA

For the Biotechnology subindustry, Ascendis Pharma AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's EV-to-EBITDA falls into.


;
;

Ascendis Pharma AS EV-to-EBITDA Calculation

Ascendis Pharma AS's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6086.821/-1431.804
=-4.25

Ascendis Pharma AS's current Enterprise Value is R$6,087 Mil.
Ascendis Pharma AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-1,432 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascendis Pharma AS  (BSP:A1SN34) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Ascendis Pharma AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=66.90/-35.570
=At Loss

Ascendis Pharma AS's share price for today is R$66.90.
Ascendis Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-35.570.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Ascendis Pharma AS EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma AS Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ascendis Pharma AS Headlines

No Headlines